UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 12, 2017
Audentes Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
001-37833 |
46-1606174 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
600 California Street, 17th Floor San Francisco, California |
|
94108 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (415) 818-1001
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 1.01 Entry into a Material Definitive Contract.
On July 12, 2017, Audentes Therapeutics, Inc. (the “Company”) entered into a lease (the “Lease”) with Britannia Gateway II Limited Partnership, pursuant to which the Company will lease an additional space, resulting in a total of 26,553 leased square feet, at 201 Gateway Boulevard in South San Francisco, California 94063. The Lease commences on February 1, 2018 for an eight-year term, with an option to extend the term for one additional eight-year period. The Company’s annual base rent for the premises will be approximately $1.5 million for the first year of the Lease, and will increase by 3% each year thereafter. Under the Lease, the Company will have approximately $1.4 million for tenant improvements.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant.
The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 12, 2017, Jonathan Silverstein notified the Company of his decision to resign from the Company’s Board of Directors effective as of the same date. Additionally, on July 12, 2017, Thomas Woiwode notified the Company of his decision to resign from the Company’s Board of Directors effective as of the same date. Neither resignation was due to any disagreement with the Company.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Audentes Therapeutics, Inc. |
|
|
|
|
|
|
|
Date: July 14, 2017 |
|
By: |
/s/ Thomas Soloway |
|
|
|
|
Thomas Soloway |
|
|
|
|
Chief Financial Officer |